Treffer 1 - 4 von 4 für Suche 'Esterberg, Lizzi', Suchdauer: 0,39s Treffer weiter einschränken
  1. 1
    Study Outcomes Among Patients with Parkinson’s Disease Treated for Psychosis Residing in the Long-Term Care Setting and Newly Initiating Pimavanserin or Off-Label Atypical Antipsychotics

    Study Outcomes Among Patients with Parkinson’s Disease Treated for Psychosis Residing in the Long-Term Care Setting and Newly Initiating Pimavanserin or Off-Label Atypical Antipsyc... von Meyers, Juliana, Nham, Tram, Wang, Stanley, Esterberg, Lizzi, Rashid, Nazia

    Veröffentlicht in CNS spectrums

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    P924: TREATMENT PATTERNS OF TRIPLE‐CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL‐WORLD OBSERVATIONAL CHART REVIEW STUDY

    P924: TREATMENT PATTERNS OF TRIPLE‐CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL‐WORLD OBSERVATIONAL CHART REVIEW S... von Goyal, Ravi K, Frugier, Gaelle, Rombi, Julien, Esterberg, Lizzi, Davis, Keith, Hlavacek, Patrick, Ren, Jinma, Schepart, Alex, Aydin, Didem, Dibonaventura, Marco

    Veröffentlicht in HemaSphere

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study

    Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study von Goyal, Ravi K., Frugier, Gaelle, Rombi, Julien, Esterberg, Lizzi, Davis, Keith L., Hlavacek, Patrick, Ren, Jinma, Schepart, Alex, Aydin, Didem, DiBonaventura, Marco

    Veröffentlicht in Journal of clinical oncology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): A SEER-Medicare analysis

    Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): A SEER-Medicare analysis von Awan, Farrukh Tauseef, Yande, Soham, Esterberg, Lizzi, Nagar, Saurabh P., Goyal, Ravi K., Priyadarshini, Masoom

    Veröffentlicht in JCO oncology practice

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: